71 results about "Skin tumor" patented technology

Methods, compositions and products for preventing skin tumor formation or inhibiting development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α2 adrenergic receptor agonist, such brimonidine.

Embodiments of the invention relate to a method of treating a cancerous or non-cancerous skin lesion of a subject, e.g. a human patient, by epidermal radioisotope therapy, a specialized type of brachytherapy. The method can include defining and marking an area of skin to be treated; covering the area with a protective layer, e.g. a protective film or foil; applying a tailor-made radioactive source by applying a layer of a radioactive source material on the protective layer, such that the area is covered by the material while any area not to be treated is spared; and removing the radioactive source after a predetermined time period of irradiation.

The present invention relates to the effect of naturally occurring compounds on tumor development. As an example of proof, we used low; non-toxic doses of three compound e.g. Calcium D-glucarate, a naturally occurring Ca++ salt of D-glucaric acid; Nicotinamide (NA), a naturally occurring vitamin and butyric acid (BA), a naturally occurring saturated short chain fatty acid. 7,12 dimethylbenzanthracene (DMBA), which is a very potent skin carcinogen and is an environmental pollutant, was used for skin tumor development. Experiment was performed up to 30 weeks. All the above-mentioned compounds were used either alone or concomitantly any two or all the three. In the positive control group 100% tumorigenesis was attained in 28 weeks, use of single compound led to the inhibition of DMBA induced tumorigenesis between 33 to 47%, use of two compounds resulted in the 73 to 80% reduction in tumorigenesis but the concomitant use of three compounds resulted into 100% inhibition of tumor development at the end of 30 weeks. This led us to conclude that the concomitant use of Cag, NA and BA in combination of two is useful for preventing skin tumor development for a sort or long period of time. But the concomitant use of all the three compounds, as described, exhibited the perfect synergistic effect in preventing the tumor development completely. This strategy should be equally effective in the management of benign and possibly malignant tumor in any organ caused by any mean.

Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α2 adrenergic receptor agonist, such as brimonidine.

Compounds of following general formula (I) and pharmaceutical compositions thereof for inhibiting mammalian tumor cell proliferation are disclosed. In formula (I), n is an integer from 0 to 9. The cell proliferation of breast tumor, ovarian tumor, skin tumor or liver tumor is inhibited by the compounds of the formula (I).